Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Doctoral Thesis (2)
Keywords
- 4-HNE (1)
- ABC-Transporter (1)
- Cholesterintransporter (1)
- D-4F (1)
- HNE (1)
- Inflammatory pain (1)
- Neuralgie (1)
- Neuropathischer Schmerz (1)
- OxPL (1)
- Oxidized phospholipids (1)
D-4F, ein ApoA-I-mimetisches Peptid, lindert mechanische Hyperalgesie nach Verabreichung an Nagetiere, die an entzündlichen und neuropathischen Schmerzen leiden. D-4F fängt proalgetische oxidierte Lipide ab – als ein solches entzündungshemmendes Medikament – aktiviert aber auch ATP-bindende Kassettentransporter (Abca1 und Abcg1) – als ein solches anti-atherosklerotisches Medikament. Ziel dieser Arbeit war es, den Einfluss von Neuropathie und deren Behandlung mit D-4F auf die Expression von Abca1/Abcg1 sowie Zytokinen zu untersuchen.
Introduction: During inflammation, reactive oxygen species (ROS) such as Hydrogen peroxide accumulate at the inflammation site and by oxidizing lipids, they produce metabolites such as 4-hydroxynonenal (4-HNE) and oxidized phospholipids (OxPLs). Transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) are ligand gated ion channels that are expressed on nociceptors and their activation elicits pain. Hydrogen peroxide and 4-HNE are endogenous ligands for TRPA1 and their role in inflammatory pain conditions has been shown. OxPLs play a major pro-inflammatory role in many pathologies including atherosclerosis and multiple sclerosis. E06/T15 is a mouse IgM mAb that specifically binds oxidized phosphatidylcholine. D-4F is an apolipoprotein A-I mimetic peptide with a very high affinity for OxPLs and possess anti-inflammatory properties. E06 mAb and D-4F peptide protect against OxPLs-induced damage in atherosclerosis in vivo.
Methods: To investigate the role of ROS and their metabolites in inflammatory pain, I utilized a combination of diverse and complex behavioral pain measurements and binding assays. I examined E06 mAb and D-4F as local treatment options for hypersensitivity evoked by endogenous and exogenous activators of TRPA1 and TRPV1 as well as in inflammatory and OxPL-induced pain models in vivo. 4-HNE, hydrogen peroxide as ROS source and mustard oil (AITC) were used to activate TRPA1, while capsaicin was used to activate TRPV1.
Results: Intraplantar injection of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) into rats’ hind paw elicited thermal and mechanical hypersensitivity. Genetic and pharmacological evidence in vivo confirmed the role of TRPA1 in OxPLs-induced hypersensitivity. OxPLs formation increased in complete Freund’s adjuvant (CFA)-induced inflamed rats’ paw. E06 mAb and D-4F prevented OxPAPC–induced mechanical and thermal hypersensitivity (hyperalgesia) as well as CFA-induced mechanical hypersensitivity. Also, all irritants induced thermal and mechanical hypersensitivity as well as affective-emotional responses and spontaneous nocifensive behaviors. E06 mAb blocked prolonged mechanical hypersensitivity by all but hydrogen peroxide. In parallel, D-4F prevented mechanical hypersensitivity induced by all irritants as well as thermal hypersensitivity induced by capsaicin and 4-HNE. In addition, competitive binding assays showed that all TRPA1/V1 agonists induced prolonged formation of OxPLs in the paw tissue explaining the anti-nociceptive properties of E06 mAb and D-4F. Finally, the potential of gait analysis as a readout for non-provoked pain behavioral measurements were examined.
Conclusion and implications: OxPLs were characterized as novel targets in inflammatory pain. Treatment with the monoclonal antibody E06 or apolipoprotein A-I mimetic peptide D-4F are suggested as potential inflammatory pain medications. OxPLs’ role in neuropathic pain is yet to be investigated.